Rotavirus Infections - Pipeline Review, H2 2016

Published: Oct, 2016 | Pages: 62 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Rotavirus Infections - Pipeline Review, H2 2016, provides an overview of the Rotavirus Infections (Infectious Disease) pipeline landscape.

Rotavirus is a virus that infects the bowels. Rotavirus is the most common cause of severe diarrhea among infants and children. Transmission of rotavirus most often occurs through fecal-oral contact. Usually, this occurs from poor hand washing or from ingestion of contaminated food or water. The virus may also be transmitted through the respiratory tract or by other body fluids, but these routes are less common. The virus may live on inanimate surfaces, such as doorknobs, toys, and hard surfaces. Symptoms may include severe diarrhea, vomiting, fever, and dehydration.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Rotavirus Infections - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Rotavirus Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Rotavirus Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Rotavirus Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 3, 1, 1, 6 and 2 respectively for Similarly, the Universities portfolio in Phase II and Discovery stages comprises 4 and 1 molecules, respectively for Rotavirus Infections.

Rotavirus Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Rotavirus Infections (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Rotavirus Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Rotavirus Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Rotavirus Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Rotavirus Infections (Infectious Disease)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Rotavirus Infections (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Rotavirus Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Rotavirus Infections Overview 7
Therapeutics Development 8
Pipeline Products for Rotavirus Infections - Overview 8
Pipeline Products for Rotavirus Infections - Comparative Analysis 9
Rotavirus Infections - Therapeutics under Development by Companies 10
Rotavirus Infections - Therapeutics under Investigation by Universities/Institutes 11
Rotavirus Infections - Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Early Stage Products 14
Rotavirus Infections - Products under Development by Companies 15
Rotavirus Infections - Products under Investigation by Universities/Institutes 16
Rotavirus Infections - Companies Involved in Therapeutics Development 17
Beijing Minhai Biotechnology Co., Ltd 17
Bharat Biotech International Limited 18
Biological E. Limited 19
Curevac AG 20
Medicago Inc. 21
MSD Wellcome Trust Hilleman Laboratories Pvt Ltd 22
Nanotherapeutics, Inc. 23
Serum Institute of India Limited 24
Shantha Biotechnics Limited 25
Sinovac Biotech Ltd. 26
Takeda Pharmaceutical Company Limited 27
Wuhan Institute of Biological Products Co., Ltd. 28
Rotavirus Infections - Therapeutics Assessment 29
Assessment by Monotherapy Products 29
Assessment by Target 30
Assessment by Route of Administration 32
Assessment by Molecule Type 34
Drug Profiles 36
Rotavac-5C - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
rotavirus (pentavalent) vaccine - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
rotavirus (tetravalent) vaccine - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
Rotavirus (virus like particle) vaccine - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
rotavirus (virus like particle) vaccine - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
rotavirus (virus like particle) vaccine - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
rotavirus [Serotype P2-VP8] (monovalent) vaccine - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
rotavirus [Serotype P2] (trivalent) vaccine - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
Rotavirus [serotypes G1, G2, G3, G4, G8, G9] (hexavalent) vaccine - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
rotavirus [serotypes G1, G2, G3, G4, G9] (pentavalent) vaccine - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
Rotavirus [serotypes G1, G2, G3, G4, G9] (pentavalent) vaccine - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
Rotavirus [serotypes G1, G2, G3, G4, P1] (pentavalent) vaccine - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
Rotavirus [serotypes G1, G2, G3, G4] (tetravalent) vaccine - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
rotavirus vaccine - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
rotavirus vaccine - Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
rotavirus vaccine - Drug Profile 52
Product Description 52
Mechanism Of Action 52
R&D Progress 52
RV-3BB - Drug Profile 53
Product Description 53
Mechanism Of Action 53
R&D Progress 53
RV-625 - Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
Rotavirus Infections - Dormant Projects 55
Rotavirus Infections - Product Development Milestones 56
Featured News & Press Releases 56
Sep 21, 2016: Batavia Biosciences receives grant to develop new vaccine against rotavirus 56
Oct 14, 2014: Shantha`s Investigational Rotavirus Vaccine Enters Phase III Clinical Trials in India 56
Jun 20, 2013: Medicago Successfully Produces Plant-based Rotavirus VLP Vaccine Candidate 57
Nov 10, 2012: GSK's Rotarix Vaccine To Help Protect Babies Against Rotavirus 57
Apr 26, 2012: GSK's Rotarix to Be Introduced in Ghana 58
Nov 21, 2011: GSK And Daiichi Sankyo To Launch Rotarix Oral Liquid Formulation To Prevent Rotavirus Gastroenteritis In Japan 58
May 19, 2010: Health Sciences Authority Provides Update On Review Of Presence Of Porcine Circovirus In GSK's Rotarix 59
Appendix 61
Methodology 61
Coverage 61
Secondary Research 61
Primary Research 61
Expert Panel Validation 61
Contact Us 61
Disclaimer 62

List of Tables

Number of Products under Development for Rotavirus Infections, H2 2016 8
Number of Products under Development for Rotavirus Infections - Comparative Analysis, H2 2016 9
Number of Products under Development by Companies, H2 2016 10
Number of Products under Investigation by Universities/Institutes, H2 2016 11
Comparative Analysis by Late Stage Development, H2 2016 12
Comparative Analysis by Clinical Stage Development, H2 2016 13
Comparative Analysis by Early Stage Development, H2 2016 14
Products under Development by Companies, H2 2016 15
Products under Investigation by Universities/Institutes, H2 2016 16
Rotavirus Infections - Pipeline by Beijing Minhai Biotechnology Co., Ltd, H2 2016 17
Rotavirus Infections - Pipeline by Bharat Biotech International Limited, H2 2016 18
Rotavirus Infections - Pipeline by Biological E. Limited, H2 2016 19
Rotavirus Infections - Pipeline by Curevac AG, H2 2016 20
Rotavirus Infections - Pipeline by Medicago Inc., H2 2016 21
Rotavirus Infections - Pipeline by MSD Wellcome Trust Hilleman Laboratories Pvt Ltd, H2 2016 22
Rotavirus Infections - Pipeline by Nanotherapeutics, Inc., H2 2016 23
Rotavirus Infections - Pipeline by Serum Institute of India Limited, H2 2016 24
Rotavirus Infections - Pipeline by Shantha Biotechnics Limited, H2 2016 25
Rotavirus Infections - Pipeline by Sinovac Biotech Ltd., H2 2016 26
Rotavirus Infections - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016 27
Rotavirus Infections - Pipeline by Wuhan Institute of Biological Products Co., Ltd., H2 2016 28
Assessment by Monotherapy Products, H2 2016 29
Number of Products by Stage and Target, H2 2016 31
Number of Products by Stage and Route of Administration, H2 2016 33
Number of Products by Stage and Molecule Type, H2 2016 35
Rotavirus Infections - Dormant Projects, H2 2016 55